<i>dACE2</i>, and to a lesser extent <i>ACE2</i>, RNA levels increased in primary bronchial cells treated with interferons and this induction was mitigated by Janus kinase (JAK) inhibitors that are used therapeutically in COVID-19 patients. This evidence concerns the gene ACE2 and COVID-19.